> For some reason the focus still seems to be largely on case counts instead of actual outcomes. For vaccines, the focus still seems to be largely the percen

> For some reason the focus still seems to be largely on case counts instead of actual outcomes. For vaccines, the focus still seems to be largely the percentage of effectiveness, as if that effectiveness will be a reliable constant for each combination of particular vaccine, particular variant, and particular undesired outcome (case, symptomatic case, hospitalized case, oxygenized case, ventilated case, long covid, death, whatever). However, that effectiveness will almost certainly vary both with the attributes of the person (e.g. age, sex and `comorbidities`) exposed to the variant and with the environment, particularly the number of times the typical vaccinated person is exposed to the variant and how heavily exposed. For example, if we now observe, when omicron is starting to spread, that a vaccine shows 50% reduction in cases or hospitalizations or deaths, what will be the observed reduction when omicron is more prevalent, when it may be common for typical persons to be exposed multiple times per day for a few weeks? Could the 50% reduction still occur? Could the vaccine give a percentage of people super-immunity and the other people none at all? Otherwise, will the increased presence of omicron in the environment overwhelm the effects of the vaccine and drive that observed reduction from vaccination (or boosterization, or whatever) down significantly? What do the experts know from experience about this? I wish Mr Biden nothing but success in his efforts to get us all doing the right thing, and I hope that his emphasis on vaccination now brings good results.